AU2019406803B2 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2019406803B2
AU2019406803B2 AU2019406803A AU2019406803A AU2019406803B2 AU 2019406803 B2 AU2019406803 B2 AU 2019406803B2 AU 2019406803 A AU2019406803 A AU 2019406803A AU 2019406803 A AU2019406803 A AU 2019406803A AU 2019406803 B2 AU2019406803 B2 AU 2019406803B2
Authority
AU
Australia
Prior art keywords
disorders
compound
compound according
disorder
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019406803A
Other languages
English (en)
Other versions
AU2019406803A1 (en
Inventor
Robert Davis
Peng Li
Yupu QIAO
Kimberly Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2019406803A1 publication Critical patent/AU2019406803A1/en
Application granted granted Critical
Publication of AU2019406803B2 publication Critical patent/AU2019406803B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2019406803A 2018-12-17 2019-12-17 Organic compounds Active AU2019406803B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
US62/780,703 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (2)

Publication Number Publication Date
AU2019406803A1 AU2019406803A1 (en) 2021-07-08
AU2019406803B2 true AU2019406803B2 (en) 2025-04-24

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019406803A Active AU2019406803B2 (en) 2018-12-17 2019-12-17 Organic compounds

Country Status (11)

Country Link
US (1) US12325726B2 (enExample)
EP (1) EP3897656A4 (enExample)
JP (1) JP7645797B2 (enExample)
KR (1) KR102931436B1 (enExample)
CN (1) CN113226326B (enExample)
AU (1) AU2019406803B2 (enExample)
BR (1) BR112021011765A2 (enExample)
CA (1) CA3121636A1 (enExample)
IL (1) IL283960B2 (enExample)
MX (1) MX2021007142A (enExample)
WO (1) WO2020131918A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
MX2021007142A (es) 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Compuestos organicos.
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
JP2023539125A (ja) * 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240589A1 (en) * 2014-10-16 2017-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
ES2296594T3 (es) 1994-02-14 2008-05-01 Euro-Celtique S.A. Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
ATE538797T1 (de) 2005-06-09 2012-01-15 Euro Celtique Sa Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
MX2021007142A (es) 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Compuestos organicos.
JP2023539125A (ja) 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240589A1 (en) * 2014-10-16 2017-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
EP3897656A4 (en) 2022-09-21
MX2021007142A (es) 2021-08-11
CN113226326B (zh) 2024-09-20
US20220073558A1 (en) 2022-03-10
WO2020131918A1 (en) 2020-06-25
CN113226326A (zh) 2021-08-06
CA3121636A1 (en) 2020-06-25
JP2022513933A (ja) 2022-02-09
IL283960B1 (en) 2025-05-01
KR20210105934A (ko) 2021-08-27
IL283960A (en) 2021-07-29
EP3897656A1 (en) 2021-10-27
IL283960B2 (en) 2025-09-01
AU2019406803A1 (en) 2021-07-08
KR102931436B1 (ko) 2026-02-25
JP7645797B2 (ja) 2025-03-14
BR112021011765A2 (pt) 2021-08-31
US12325726B2 (en) 2025-06-10

Similar Documents

Publication Publication Date Title
AU2019406803B2 (en) Organic compounds
EP4200312A1 (en) Organic compounds
JP7387590B2 (ja) ラパマイシン誘導体
JP2019512528A (ja) 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
US10519193B2 (en) Steroidal compound, composition containing the same and use thereof
CN114206899A (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
CA3182354A1 (en) Methyl 2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1h-cyclopenta[b]pyridine-3-carboxylates and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates as cav1.2 activators
JP2021500309A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
JP7750582B2 (ja) 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途
RU2809023C2 (ru) Органические соединения
HK40058207A (en) Organic compounds
EP4165048B1 (en) Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators
EP3778589B1 (en) 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
US20250163062A1 (en) Wnt pathway inhibitor compounds
HK40058207B (zh) 有机化合物
JP2024545200A (ja) ＣａＶ１．２活性剤としてのピリジン－３－カルボキシレート化合物
HK40082497A (en) Fused imidazole derivatives, preparation method and medical use thereof
HK40104271A (en) Steroid compound, and pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)